Actuate Therapeutics (ACTU) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket One (RKTO) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 59.1% versus a loss of 90.3%. Rocket One is the larger company by market cap ($16.2 million vs $14.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | RKTO |
|---|---|---|
| Share price | $0.6102 | $0.6493 |
| Market cap | $14.65M | $16.17M |
| 1-day change | -10.13% | +0.50% |
| YTD return | -88.91% | -34.74% |
| 1-year return | -90.31% | -59.11% |
| 5-year return | — | -97.77% |
| EPS (TTM) | $-0.87 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $2.45 |
| 52-week low | $0.604 | $0.489 |
| Distance from 52-week high | -92.81% | -73.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +1814.13% | — |
| Average volume | 386.51K | 630.66K |
| Shares outstanding | 24.01M | 24.90M |
| Employees | 12 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RKTO has outperformed ACTU by 31.2 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ACTU vs RKTO FAQ
Which is bigger, Actuate Therapeutics or Rocket One?
Rocket One (RKTO) is larger, with a market capitalization of $16.17M compared with $14.65M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or RKTO?
RKTO returned -59.11% over the past 12 months, compared with -90.31% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.